1. Barlesi F, Park K, Ciradiello F, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLC. ESMO Congress 2016, Abstr. LBA44_PR.
2. Barlesi F, Steins M, Horn L, et al. Checkmate 017/057: Nivolumab vs. docetaxel – Updated analysis with 2 years minimum follow-up. ESMO 2016, Abstr. 1215PD.
3. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627–39.
4. Borghaei H, Paz-Ares L, Horn L, et al. Supplement to: Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 2015;373(Suppl):1627–39.
5. Brahmer J, Reckamp K, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–35.
6. Chen D, Irving I, Hodi S. Molecular pathways: Next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Cancer Res 2012;18:6580–7.
7. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1–10.
8. Chiorean E, Hurwitz H. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol 2015;23:1230–7.
9. Cook K, Figg W. Angiogenesis inhibitors – Current strategies and future prospects. CA Cancer J Clin 2010;60:222–43.
10. Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther 2011;11:1223–31.
11. Duell T, Kappler S, Knöferl B, et al. Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced NSCLC. Cancer Treat Com 2015;4:106–12.
12. Eberhardt W, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 2015;26:1573–88.
13. Garon E, Ciuleanu TE, Arrietta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665–73.
14. Garon EB, Rivzi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018–28.
15. Goeckenjan G, Sitter H, Thomas M, et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Pneumologie 2010;64(S 02):e1, e164.
16. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016;11:39–51.
17. Goss G, Tsai C, Shepherd F, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016;17:1643–52.
18. Herbst R, Baas P, Kim D. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–50.
19. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1- immunohistochemistry in lung cancer – In what state is this art? J Thorac Oncol 2015;10:985–89.
20. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagnostics 2013;15:415–53.
21. Mok T, Wu Y, Ahn M, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Eng J Med 2016; doi: 10.1056/NEJMoa1612674 [Epub ahead of print].
22. Novello, Barlesi F, Califano R, et al. (2016) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(Suppl 5):v1–27.
23. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64.
24. Paz-Ares L, Marinis F, Dediu M. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895–902.
25. Paz-Ares L, Socinski MA, Shahidi J, et al. Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (sq-NSCLC). European Lung Cancer Conference 2016; elcc2016.org.
26. Paz-Ares L, Tan EH, Zhang L, et al. Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7). ESMO 2016, Abstract #LBA43.
27. Peters S, Zimmermann S, Adjei A. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev 2014;40:917–26.
28. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974–82.
29. Reck M, Kaiser R, Douillard JY, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143–55.
30. Reck M, Rodriguez-Abreu D, Robinson A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33.
31. Reck M, Thomas M, Kropf-Sanchen C, et al. Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR-expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE). Oncol Res Treat 2016;39:539–47.
32. Rizvi N, Hellmann M, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–8.
33. Sandler, Gray R. Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–50.
34. Scagliotti G, Kim TM, Crinò et al. Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study. ESMO 2016, Abstract LBA42_PR.
35. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. JCO 2008;26:3543–51.
36. Scheel A, Dietel M, Heukamp L, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous cell and adenocarcinoma. Mod Pathol 2016;10:1165–72.
37. Schiller JH, Harrington D, Belnani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–8.
38. Sequist L, Yang J, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–34.
39. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189–97.
40. Shaw AT, Ou S, Bang Y, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963–71.
41. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology Provisional Clinical Opinion: The integration of palliative care into standard oncology care. J Clin Oncol 2012;30:880–7.
42. Socinski, Creelan B, Horn L, et al. CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice of platinum-based doublet chemotherapy as first-line therapy for stage IV/recurrent programmed death ligand 1-positive NSCLC. ESMO 2016, Abstract LBA7_PR.
43. Solomon B, Mok T, Kim D, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
44. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 2011;41:297–311.
45. Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016;8:32–47.
46. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16:763–74.
47. Travis WD, Brambilla E, Nicholson A, et al. The 2015 World Health Organization Classification of lung tumors. J Thorac Oncol 2015;10:1243–60.
48. Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25:1462–74.
49. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory Investigation 2014;94:107–16.
50. Yang J, Riella LV, Chock S, et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 2011;187:1113–9.
51. Zietemann V, Duell T. Every-day clinical practice in patients with advanced non-small-cell lung cancer. Lung Cancer 2010;68:273–7.
Priv.-Doz. Dr. med. Thomas Duell, Asklepios Lungenfachkliniken, Robert-Koch-Allee 2, 82131 Gauting, E-Mail: firstname.lastname@example.org